Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.
Gilles R DagenaisLars RydénLawrence A LeiterMark LakshmananLeanne DyalJeffrey L ProbstfieldCharles Messan AtissoJonathan E ShawIgnacio CongetWilliam C CushmanPatricio Lopez-JaramilloFernando LanasErnesto German Cordona MunozValdis PiragsNana PogosovaJan BasileWayne H H SheuTheodora Temelkova-KurktschievPeter J RaubenheimerMatyas KeltaiStephanie HallPrem PaisHelen M ColhounMatthew C RiddleHertzel C GersteinPublished in: Cardiovascular diabetology (2020)
https://www.clinicaltrials.gouv . Unique Identifier NCT01394952).